Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors

Amber C. Miller, Stephen J Russell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Oncolytic viruses are a promising experimental anticancer therapy currently undergoing clinical translation. The development of oncolytic virotherapy offers a potential solution to the elusive "one-shot" cancer cure by providing targeted therapy to selectively infect and kill cancer cells while provoking adaptive anticancer immune responses as protection against distant metastasis and recurrent tumor challenge. While this technology has overcome barriers to safety and efficacy through cancer-specific targeting techniques, in order to reach full therapeutic potential, oncolytic therapies must still overcome barriers to intratumoral delivery and spread that result in heterogeneous intratumoral delivery and nonuniform response. This review will discuss barriers to oncolytic virotherapy translation related to mechanisms of delivering virus via tumor vasculature and distributing virus throughout the tumor microenvironment. Barriers include extravasation into the tumor that is dependent on adequate blood flow, tissue perfusion, and tumoral enhanced permeability and retention for transvascular transport. Subsequently, virions must undergo interstitial transport against dense stromal barriers and high interstitial fluid pressure to initiate infection. In order to achieve massive tumor regression, infection must spread to cover large volumes of tumor mass. Furthermore, virus bioavailability is quickly dampened upon systemic administration due to neutralization and sequestration. These barriers to delivery limit the amount of virus that effectively reaches and spreads within the tumor, forcing dose increases that impinge upon limits of production and increase possibility of adverse events. Techniques to overcome these barriers are discussed but largely remain to be translated into clinical use.

Original languageEnglish (US)
Pages (from-to)11-31
Number of pages21
JournalVirus Adaptation and Treatment
Volume6
Issue number1
DOIs
StatePublished - Jul 29 2014

Fingerprint

Oncolytic Virotherapy
Neoplasms
Viruses
Oncolytic Viruses
Oncogenic Viruses
Investigational Therapies
Tumor Microenvironment
Extracellular Fluid
Adaptive Immunity
Infection
Tumor Burden
Virion
Biological Availability
Permeability
Therapeutics
Perfusion
Neoplasm Metastasis
Technology
Safety
Pressure

Keywords

  • Barriers
  • Delivery
  • Oncolytic virotherapy
  • Systemic therapy
  • Translation

ASJC Scopus subject areas

  • Virology
  • Immunology
  • Infectious Diseases

Cite this

Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. / Miller, Amber C.; Russell, Stephen J.

In: Virus Adaptation and Treatment, Vol. 6, No. 1, 29.07.2014, p. 11-31.

Research output: Contribution to journalArticle

@article{1b5d8052995141109b250b77aa45645e,
title = "Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors",
abstract = "Oncolytic viruses are a promising experimental anticancer therapy currently undergoing clinical translation. The development of oncolytic virotherapy offers a potential solution to the elusive {"}one-shot{"} cancer cure by providing targeted therapy to selectively infect and kill cancer cells while provoking adaptive anticancer immune responses as protection against distant metastasis and recurrent tumor challenge. While this technology has overcome barriers to safety and efficacy through cancer-specific targeting techniques, in order to reach full therapeutic potential, oncolytic therapies must still overcome barriers to intratumoral delivery and spread that result in heterogeneous intratumoral delivery and nonuniform response. This review will discuss barriers to oncolytic virotherapy translation related to mechanisms of delivering virus via tumor vasculature and distributing virus throughout the tumor microenvironment. Barriers include extravasation into the tumor that is dependent on adequate blood flow, tissue perfusion, and tumoral enhanced permeability and retention for transvascular transport. Subsequently, virions must undergo interstitial transport against dense stromal barriers and high interstitial fluid pressure to initiate infection. In order to achieve massive tumor regression, infection must spread to cover large volumes of tumor mass. Furthermore, virus bioavailability is quickly dampened upon systemic administration due to neutralization and sequestration. These barriers to delivery limit the amount of virus that effectively reaches and spreads within the tumor, forcing dose increases that impinge upon limits of production and increase possibility of adverse events. Techniques to overcome these barriers are discussed but largely remain to be translated into clinical use.",
keywords = "Barriers, Delivery, Oncolytic virotherapy, Systemic therapy, Translation",
author = "Miller, {Amber C.} and Russell, {Stephen J}",
year = "2014",
month = "7",
day = "29",
doi = "10.2147/VAAT.S50110",
language = "English (US)",
volume = "6",
pages = "11--31",
journal = "Virus Adaptation and Treatment",
issn = "1179-1624",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors

AU - Miller, Amber C.

AU - Russell, Stephen J

PY - 2014/7/29

Y1 - 2014/7/29

N2 - Oncolytic viruses are a promising experimental anticancer therapy currently undergoing clinical translation. The development of oncolytic virotherapy offers a potential solution to the elusive "one-shot" cancer cure by providing targeted therapy to selectively infect and kill cancer cells while provoking adaptive anticancer immune responses as protection against distant metastasis and recurrent tumor challenge. While this technology has overcome barriers to safety and efficacy through cancer-specific targeting techniques, in order to reach full therapeutic potential, oncolytic therapies must still overcome barriers to intratumoral delivery and spread that result in heterogeneous intratumoral delivery and nonuniform response. This review will discuss barriers to oncolytic virotherapy translation related to mechanisms of delivering virus via tumor vasculature and distributing virus throughout the tumor microenvironment. Barriers include extravasation into the tumor that is dependent on adequate blood flow, tissue perfusion, and tumoral enhanced permeability and retention for transvascular transport. Subsequently, virions must undergo interstitial transport against dense stromal barriers and high interstitial fluid pressure to initiate infection. In order to achieve massive tumor regression, infection must spread to cover large volumes of tumor mass. Furthermore, virus bioavailability is quickly dampened upon systemic administration due to neutralization and sequestration. These barriers to delivery limit the amount of virus that effectively reaches and spreads within the tumor, forcing dose increases that impinge upon limits of production and increase possibility of adverse events. Techniques to overcome these barriers are discussed but largely remain to be translated into clinical use.

AB - Oncolytic viruses are a promising experimental anticancer therapy currently undergoing clinical translation. The development of oncolytic virotherapy offers a potential solution to the elusive "one-shot" cancer cure by providing targeted therapy to selectively infect and kill cancer cells while provoking adaptive anticancer immune responses as protection against distant metastasis and recurrent tumor challenge. While this technology has overcome barriers to safety and efficacy through cancer-specific targeting techniques, in order to reach full therapeutic potential, oncolytic therapies must still overcome barriers to intratumoral delivery and spread that result in heterogeneous intratumoral delivery and nonuniform response. This review will discuss barriers to oncolytic virotherapy translation related to mechanisms of delivering virus via tumor vasculature and distributing virus throughout the tumor microenvironment. Barriers include extravasation into the tumor that is dependent on adequate blood flow, tissue perfusion, and tumoral enhanced permeability and retention for transvascular transport. Subsequently, virions must undergo interstitial transport against dense stromal barriers and high interstitial fluid pressure to initiate infection. In order to achieve massive tumor regression, infection must spread to cover large volumes of tumor mass. Furthermore, virus bioavailability is quickly dampened upon systemic administration due to neutralization and sequestration. These barriers to delivery limit the amount of virus that effectively reaches and spreads within the tumor, forcing dose increases that impinge upon limits of production and increase possibility of adverse events. Techniques to overcome these barriers are discussed but largely remain to be translated into clinical use.

KW - Barriers

KW - Delivery

KW - Oncolytic virotherapy

KW - Systemic therapy

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=84905238524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905238524&partnerID=8YFLogxK

U2 - 10.2147/VAAT.S50110

DO - 10.2147/VAAT.S50110

M3 - Article

AN - SCOPUS:84905238524

VL - 6

SP - 11

EP - 31

JO - Virus Adaptation and Treatment

JF - Virus Adaptation and Treatment

SN - 1179-1624

IS - 1

ER -